Barbie just released a doll with diabetes. Here's why a B.C. content creator is calling it 'incredible'
When Bella Bucchiotti was 19, she was diagnosed with Type 1 diabetes (T1D).
'It came completely out of the blue, and adjusting to life with T1D was overwhelming,' the B.C.-based content creator and founder of the site xoxobella.com recalls. 'There's no easing into it — one day you're fine, and the next you're figuring out insulin doses and how every bite of food might impact your blood sugar.'
A chronic autoimmune disease that prevents your pancreas from making insulin, people with T1D require insulin therapies in order to survive.
The diagnosis changed everything for Bucchiotti. Life, she says, became a constant balancing act.
'No one really sees all the mental load that comes with it,' Bucchiotti says. 'There's a huge learning curve, especially at the start — figuring out how your body responds to food, exercise, stress, even lack of sleep. Every day is different, and that can be exhausting.'
Developing the tools and knowledge to help manage her diabetes, Bucchiotti says she's learned to live with Type 1, without letting it define her.
Bucchiotti isn't alone in her diagnosis. According to the research and advocacy organization Breakthrough T1D, about 300,000 Canadians have T1D, with that number forecast to increase to 455,580 by 2040.
Most diagnoses come between ages 10 and 14, according to Breakthrough T1D. But a diagnosis can come at any age. And that diagnosis can come as a shock.
Looking to raise awareness about Type 1 diabetes, Mattel Inc. is releasing its first Barbie doll with the disease. The move, Bucchiotti says, could be helpful to people, especially young girls, who might be facing a T1D diagnosis.
'It's a way of being seen and not singled out,' she says. 'That really matters, especially in the beginning when you're learning how to manage it all and you feel so different from everyone around you.'
As a new mother, Bucchiotti says the representation can impart an important message to children living with T1D: 'You're not broken, and you're not alone.'
'The mental-health side of diabetes is something we don't talk about enough, especially the isolation,' she says. 'A toy like this sends a message that living with Type 1 diabetes is just one part of who you are, and it doesn't have to make you feel like you don't belong.'
Created in partnership with Breakthrough T1D, the new doll wears a continuous glucose monitor (CGM), an important tool that measures a person's blood-glucose level, held in place with a Barbie-pink piece of heart-shaped medical tape.
'Even now, seeing someone else with an insulin pump or CGM at the coffee shop makes me feel like I'm not alone,' Bucchiotti notes of the noticeable inclusion. 'That quiet connection is something really special, because no one else quite understands how tough some days can be.'
The doll also features an insulin pump, a small device that allows for insulin dosing as needed, at the waist.
'It gives kids someone — even in doll-form — who truly reflects their experience,' Bucchiotti remarks of the realistic elements of the polka-dot-dress-wearing Barbie. 'Instead of feeling different or ashamed, they see something familiar, something that makes their condition feel normal.
'A Barbie with a CGM might seem like a small gesture, but for a child navigating a life-changing diagnosis, it can bring comfort, confidence and a sense of belonging. It can also open the door for conversations with friends and classmates, helping to build empathy and break down stigma.'
Part of the Barbie Fashionistas' line, the Barbie doll with Type 1 joins a collection of more than 175 looks who feature a wide variety of skin tones, eye and hair colours, body types, ethnicities, disabilities and more.
The latest doll reflects an 'important step' in Mattel Inc.'s commitment to inclusivity and representation, according to Krista Berger, senior vice-president of Barbie and global head of dolls.
For Bucchiotti, the doll represents an important point of connection for the community of people around the world living with the disease.
'Type 1 diabetes is relentless, but it builds a kind of strength you don't expect,' she says. 'It's not always easy, but the T1D community is incredibly supportive.
'Sometimes it's a message from someone who's been there, or even just spotting a CGM on a stranger across the room — those small moments of connection remind you that you're not in this alone.'
Aharris@postmedia.com
Opinion: Living with multiple sclerosis is difficult. Living in B.C. makes it harder
Margot Robbie would like to make a Barbie musical
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
3 hours ago
- Medscape
Rethinking GI Prophylaxis for the Critically Ill
Prevention doesn't come easy. The bar is high. The decision to act medically because an untoward outcome could occur means creating intervention side-effect risk that's otherwise absent. Large patient numbers must be subjected to that side-effect risk to obtain net benefit. Last, your bedside modeling must be tight, and in medicine it never is. The story of gastrointestinal (GI) prophylaxis in ICU highlights these challenges. It is best told by Deborah Cook, the godmother of ICU research. It's told through her work. She's randomized more patients than a sequence generator. Her name is the most critical MeSH term for your systematic review. If Churg, Strauss, and Wegener hadn't ruined the disease eponym practice, she'd have several to her name. Just as well; we're all transgressing some currently unidentified but soon-to-be-coined "-ism." Cook's work has dominated the GI prophylaxis space since the early 1990s. If you're new to it, start with her New England Journal of Medicine (NEJM) review from 2018. It was published on the heels of the latest randomized control trial on GI prophylaxis in the ICU. The SUP-ICU trial, which randomized patients to pantoprazole vs placebo and was also published in NEJM, had equivocal results. The accompanying editorial provided a tepid endorsement of continued prophylaxis with proton pump inhibitors (PPI), but only for those at high risk for bleeding. Two years later, a systematic review and another randomized trial (PEPTIC) found a mortality signal with PPIs, but in the wrong direction. This drove some back to H2 blockers even though they are less effective than PPI for preventing bleeding. Where I practice I see an equal number of ICU patients on PPI or H2 blockers. There seems to be no clear preference or consensus. The indomitable Dr Cook just investigated the mortality difference in the REVISE trial, published last year. She and her colleagues also produced an updated systematic review. REVISE made me feel better. I've been a PPI-for-prophylaxis guy for anyone on mechanical ventilation. I held on after PEPTIC and SUP-ICU created doubt, and REVISE seemed to vindicate my practice. REVISE found that PPI decreased bleeding without increasing mortality. PPI didn't increase pneumonia or Clostridioides difficile infections either. Unfortunately, it's never that simple. The mortality signal was still present in the updated systematic review. The mortality "noise" is dependent on severity of illness. It's the sicker patients who have a higher mortality when given PPI for prophylaxis. Why? I'm not sure. The pneumonia and C diff associations were absent in SUP-ICU, REVISE, and the updated systematic review. The systematic review authors list multiple possible explanations, given that PPI are associated with an altered microbiome, endothelial changes, and delirium. If there is a causal mechanism affecting mortality, it's not clear why the direction is discordant across levels of illness severity. Conclusions drawn by the editorials accompanying SUP-ICU and REVISE are also discordant. Seven years ago, the idea was that PPIs were most beneficial in those who are 'seriously ill with a high risk of complications.' Fast-forward and the REVISE editorial suggests PPI for those on mechanical ventilation and an APACHE II score of less than 25. Figure 2 in Dr Cook's 2018 review lists risk factors for bleeding— lots of overlap with the APACHE and other illness severity scores. Can a patient be at high bleeding risk but have an APACHE II score less than 25? I'm sure they can, but that needle won't be easy to thread at the bedside. Can Dr Cook snatch clarity from the jaws of this data quagmire? Perhaps. Her group just published another paper on GI bleeding in the ICU. The focus was on bleeding events that are considered important by ICU survivors and family members. This was a preplanned analysis of data from the REVISE trial. PPI shined again, reducing patient-important events regardless of illness severity. They used a proportional hazards model, that accounts for the competing risk for death, to analyze their primary outcome. Not sure if this provides clarity per se but it does make me feel better about continuing to use prophylactic PPI for my mechanically ventilated patients.
Yahoo
7 hours ago
- Yahoo
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ('BriaCell' or the 'Company'), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of a key clinical site, Mayo Clinic, to its ongoing pivotal Phase 3 clinical study ( as NCT06072612) in metastatic breast cancer. BriaCell's Phase 3 study now has 69 active clinical sites across 15 states, including Mayo Clinic, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, Northwestern University, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Texas Oncology-Baylor Charles A. Sammons Cancer Center, and University of Arizona. 'We are very excited to be working with renowned clinical experts at a leading cancer center like Mayo Clinic, who also participated in BriaCell's Phase 2 study,' stated Dr. Giuseppe Del Priore, BriaCell's Chief Medical Officer. 'We strongly believe that our novel immunotherapy has the potential to transform cancer care for patients and their families.' BriaCell's pivotal Phase 3 clinical study is evaluating BriaCell's lead clinical candidate, Bria-IMT™, plus immune check point inhibitor (CPI) versus physician's choice in advanced metastatic breast cancer (Bria-ABC). Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice as the primary endpoint. BriaCell recently (ASCO 2025) announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA Fast Track designation. For additional information on BriaCell's pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit NCT06072612. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at Safe Harbor This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the Company's beliefs regarding the potential of the Bria-IMT therapy to transform cancer care; the Company's anticipated timeline for analyzing interim data; the Company's analysis of interim data are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 'Risks and Uncertainties' in the Company's most recent Management's Discussion and Analysis, under the heading 'Risk Factors' in the Company's most recent Annual Information Form, and under 'Risks and Uncertainties' in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at and on EDGAR at Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@ Investor Relations Contact:investors@
Yahoo
7 hours ago
- Yahoo
Northwest Healthcare Properties Real Estate Investment Trust Announces July 2025 Distribution
Toronto, Ontario--(Newsfile Corp. - July 15, 2025) - Northwest Healthcare Properties Real Estate Investment Trust (TSX: (the "REIT" or "Northwest"), a leading owner and operator of healthcare real estate infrastructure in North America, Brazil, Europe and Australasia, announced today that the Trustees of the REIT have declared a distribution of $0.03 per unit for the month of July 2025, representing $0.36 per unit on an annualized basis. The distribution will be payable on August 15, 2025, to unitholders of record as at July 31, 2025. Northwest offers a distribution reinvestment plan (the "DRIP"). On each distribution date, eligible unitholders registered in the DRIP will have their cash distributions reinvested to purchase Trust Units and will also receive bonus Trust Units equal to 3% of their cash distributions. Complete details of the DRIP are available on the REIT's website at About Northwest Northwest provides investors with access to a portfolio of high-quality international healthcare real estate infrastructure comprised as at May 14, 2025, of interests in a diversified portfolio of 169 income-producing properties and 15.8 million square feet of gross leasable area located throughout major markets in North America, Brazil, Europe, and Australasia. The REIT's portfolio of medical outpatient buildings, clinics, and hospitals is characterized by long-term indexed leases and stable occupancies. Northwest leverages its global workforce in eight countries to serve as a long-term real estate partner to leading healthcare operators. For additional information please visit: Contacts: Zach Vaughan, CEO, Stephanie Karamarkovic, CFO, Alyssa Barry, Investor Relations, investors@ (416) 366-2000 Ext. 2202 To view the source version of this press release, please visit Sign in to access your portfolio